Global Ophthalmic Drugs Market 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,750	207 Pages	Triton Market Research	April, 2024	TRTN18748642

Best Price Guarantee
Price	from $2,750
Length	207 Pages
Publisher	Triton Market Research
Published Date	April, 2024
SKU	TRTN18748642

Global Ophthalmic Drugs Market 2023-2030

Market Outlook

Based on Triton’s research report, the global ophthalmic drugs market is estimated to advance with a CAGR of 6.64% during the forecast period 2023-2030.

The ophthalmic market’s growth is prompted by varied factors, including the aging population being vulnerable to eye disorders. In recent years, several new technologies regarding drug delivery have also affected the market positively. Additionally, lifestyle changes and unhealthy diet patterns have resulted in an escalating incidence of ocular diseases, which drives the demand for ophthalmic drugs.

On the contrary, strict timelines for product approval and regulatory norms associated with the quality of ophthalmic drugs affect the market. Also, the patient’s concerns regarding the after-effects of ophthalmic drug dosage hamper the growth of the studied market.

REGIONAL OUTLOOK

The global ophthalmic drugs market covers Latin America, Asia-Pacific, Europe, North America, and the Middle East and Africa regions.

Asia-Pacific is expected to undergo the fastest growth over the forecast period. Encompassing India, Japan, New Zealand, South Korea, Australia, ASEAN countries, and the Rest of Asia-Pacific, this regional market is set for rapid expansion of health infrastructure. In addition to that, technological advancements coupled with changing demography will fuel the ophthalmic drugs market.

Competitive Outlook

The major market players in the ophthalmic drugs market are Novartis AG, Sun Pharmaceutical Industries Ltd, Thea Pharma Inc, Pfizer Inc, Johnson & Johnson, Accutome Inc, Genentech Inc, Regeneron Pharmaceuticals Inc, Bausch Health Companies Inc, and Abbvie Inc.

Thea Pharma Inc is a pharmaceutical company that specializes in commercialized eye care products. Its product offering includes a portfolio of seven leading eye-care products that are regulated or approved by the US Food and Drug Administration (FDA), including Zioptan®, AcellFX™, Cosopt®, Cosopt® PF, and Azasite®. It operates in North America and is headquartered in Massachusetts, the United States.

1. Global Ophthalmic Drugs Market - Summary
2. Industry Outlook: 2.1. Technology Snapshot; 2.2. Impact Analysis On The Ophthalmic Drugs Market; 2.2.1. Covid-19 Impact On The Ophthalmic Drugs Market; 2.3. Porter’s Five Forces Analysis; 2.3.1. Threat Of New Entrants; 2.3.2. Threat Of Substitutes; 2.3.3. Bargaining Power Of Buyers; 2.3.4. Bargaining Power Of Suppliers; 2.3.5. Threat Of Competitive Rivalry; 2.4. Market Maturity Analysis; 2.5. Regulatory Framework; 2.6. Key Buying Impact Analysis; 2.7. Key Market Strategies; 2.7.1. Collaborations; 2.7.2. Product Launches; 2.7.3. Mergers & Acquisitions; 2.8. Market Drivers; 2.8.1. Aging Population Vulnerable To Eye Disorders; 2.8.2. Progress In Drug Delivery Technologies; 2.8.3. Escalating Incidence Of Ocular Diseases; 2.8.4. Reimbursement Policies By Healthcare Systems; 2.9. Market Challenges; 2.9.1. Challenging Timelines For Products Approval; 2.9.2. Adverse Effects Associated With Ophthalmic Drug Usage; 2.10. Market Opportunities; 2.10.1. Surge In Interest Regarding Topically Administered Ophthalmic Drugs; 2.10.2. Increase In Approvals For Innovative Ophthalmic Therapies; 2.11. Analyst Perspective
3. Global Ophthalmic Drugs Market – By Type: 3.1. Prescription Drugs; 3.2. Over-the-counter Drugs
4. Global Ophthalmic Drugs Market – By Condition: 4.1. Dry Eye; 4.2. Glaucoma; 4.3. Infection/Inflammation/Allergies; 4.4. Retinal Disorder; 4.4.1. Wet-age Related Macular Degeneration; 4.4.2. Dry-age Related Macular Degeneration; 4.4.3. Diabetic Retinopathy; 4.4.4. Other Retinal Disorders; 4.5. Other Conditions
5. Global Ophthalmic Drugs Market – By Therapeutic Type: 5.1. Anti-glaucoma; 5.2. Anti-infection; 5.3. Anti-inflammatory; 5.4. Anti-allergy; 5.5. Other Therapeutic Types
6. Global Ophthalmic Drugs Market – By Delivery Method: 6.1. Gels; 6.2. Eye Solutions & Suspensions; 6.3. Capsules & Tablets; 6.4. Eye Drops; 6.5. Ointments
7. Global Ophthalmic Drugs Market – By Channel: 7.1. Hospital Pharmacies; 7.2. Drug Stores; 7.3. Online Pharmacies; 7.4. Other Channels
8. Global Ophthalmic Drugs Market – By Regional Outlook: 8.1. North America; 8.1.1. Market By Type; 8.1.2. Market By Condition; 8.1.2.1. Market By Retinal Disorder; 8.1.3. Market By Therapeutic Type; 8.1.4. Market By Delivery Method; 8.1.5. Market By Channel; 8.1.6. Country Analysis; 8.1.6.1. United States; 8.1.6.1.1. United States Ophthalmic Drugs Market Forecast & Prospects; 8.1.6.2. Canada; 8.1.6.2.1. Canada Ophthalmic Drugs Market Forecast & Prospects; 8.2. Europe; 8.2.1. Market By Type; 8.2.2. Market By Condition; 8.2.2.1. Market By Retinal Disorder; 8.2.3. Market By Therapeutic Type; 8.2.4. Market By Delivery Method; 8.2.5. Market By Channel; 8.2.6. Country Analysis; 8.2.6.1. United Kingdom; 8.2.6.1.1. United Kingdom Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.2. Germany; 8.2.6.2.1. Germany Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.3. France; 8.2.6.3.1. France Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.4. Italy; 8.2.6.4.1. Italy Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.5. Spain; 8.2.6.5.1. Spain Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.6. Poland; 8.2.6.6.1. Poland Ophthalmic Drugs Market Forecast & Prospects; 8.2.6.7. Rest Of Europe; 8.2.6.7.1. Rest Of Europe Ophthalmic Drugs Market Forecast & Prospects; 8.3. Asia-pacific; 8.3.1. Market By Type; 8.3.2. Market By Condition; 8.3.2.1. Market By Retinal Disorder; 8.3.3. Market By Therapeutic Type; 8.3.4. Market By Delivery Method; 8.3.5. Market By Channel; 8.3.6. Country Analysis; 8.3.6.1. China; 8.3.6.1.1. China Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.2. Japan; 8.3.6.2.1. Japan Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.3. India; 8.3.6.3.1. India Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.4. South Korea; 8.3.6.4.1. South Korea Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.5. Asean Countries; 8.3.6.5.1. Asean Countries Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.6. Australia & New Zealand; 8.3.6.6.1. Australia & New Zealand Ophthalmic Drugs Market Forecast & Prospects; 8.3.6.7. Rest Of Asia-pacific; 8.3.6.7.1. Rest Of Asia-pacific Ophthalmic Drugs Market Forecast & Prospects; 8.4. Latin America; 8.4.1. Market By Type; 8.4.2. Market By Condition; 8.4.2.1. Market By Retinal Disorder; 8.4.3. Market By Therapeutic Type; 8.4.4. Market By Delivery Method; 8.4.5. Market By Channel; 8.4.6. Country Analysis; 8.4.6.1. Brazil; 8.4.6.1.1. Brazil Ophthalmic Drugs Market Forecast & Prospects; 8.4.6.2. Mexico; 8.4.6.2.1. Mexico Ophthalmic Drugs Market Forecast & Prospects; 8.4.6.3. Rest Of Latin America; 8.4.6.3.1. Rest Of Latin America Ophthalmic Drugs Market Forecast & Prospects; 8.5. Middle East And Africa; 8.5.1. Market By Type; 8.5.2. Market By Condition; 8.5.2.1. Market By Retinal Disorder; 8.5.3. Market By Therapeutic Type; 8.5.4. Market By Delivery Method; 8.5.5. Market By Channel; 8.5.6. Country Analysis; 8.5.6.1. United Arab Emirates; 8.5.6.1.1. United Arab Emirates Ophthalmic Drugs Market Forecast & Prospects; 8.5.6.2. Turkey; 8.5.6.2.1. Turkey Ophthalmic Drugs Market Forecast & Prospects; 8.5.6.3. Saudi Arabia; 8.5.6.3.1. Saudi Arabia Ophthalmic Drugs Market Forecast & Prospects; 8.5.6.4. South Africa; 8.5.6.4.1. South Africa Ophthalmic Drugs Market Forecast & Prospects; 8.5.6.5. Rest Of Middle East & Africa; 8.5.6.5.1. Rest Of Middle East & Africa Ophthalmic Drugs Market Forecast & Prospects
9. Competitive Landscape: 9.1. Abbvie Inc; 9.1.1. Overview; 9.1.2. Product Portfolio; 9.1.3. Key Strengths; 9.1.4. Key Challenges; 9.2. Bausch Health Companies Inc; 9.2.1. Overview; 9.2.2. Product Portfolio; 9.2.3. Key Strengths; 9.2.4. Key Challenges; 9.3. Johnson & Johnson; 9.3.1. Overview; 9.3.2. Product Portfolio; 9.3.3. Key Strengths; 9.3.4. Key Challenges; 9.4. Novartis Ag; 9.4.1. Overview; 9.4.2. Product Portfolio; 9.4.3. Key Strengths; 9.4.4. Key Challenges; 9.5. Regeneron Pharmaceuticals Inc; 9.5.1. Overview; 9.5.2. Product Portfolio; 9.5.3. Key Strengths; 9.5.4. Key Challenges; 9.6. Sun Pharmaceutical Industries Ltd; 9.6.1. Overview; 9.6.2. Product Portfolio; 9.6.3. Key Strengths; 9.6.4. Key Challenges; 9.7. Accutome Inc; 9.7.1. Overview; 9.7.2. Product Portfolio; 9.7.3. Key Strengths; 9.7.4. Key Challenges; 9.8. Genentech Inc; 9.8.1. Overview; 9.8.2. Product Portfolio; 9.8.3. Key Strengths; 9.8.4. Key Challenges; 9.9. Thea Pharma Inc; 9.9.1. Overview; 9.9.2. Product Portfolio; 9.9.3. Key Strengths; 9.9.4. Key Challenges; 9.10. Pfizer Inc; 9.10.1. Overview; 9.10.2. Product Portfolio; 9.10.3. Key Strengths; 9.10.4. Key Challenges
10. Research Methodology & Scope: 10.1. Research Scope & Deliverables; 10.2. Sources Of Data; 10.3. Research Methodology
Tables List: Table 1: Global Ophthalmic Drugs Market, By Regional Outlook, 2023-2030 (In $ Million); Table 2: Regulatory Framework; Table 3: List Of Collaborations; Table 4: List Of Product Launches; Table 5: List Of Mergers & Acquisitions; Table 6: Global Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 7: Global Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 8: Global Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 9: Global Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 10: Global Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 11: Global Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million); Table 12: Global Ophthalmic Drugs Market, By Regional Outlook, 2023-2030 (In $ Million); Table 13: North America Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 14: North America Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 15: North America Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 16: North America Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 17: North America Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 18: North America Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 19: North America Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million); Table 20: Europe Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 21: Europe Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 22: Europe Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 23: Europe Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 24: Europe Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 25: Europe Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 26: Europe Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million); Table 27: Asia-pacific Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 28: Asia-pacific Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 29: Asia-pacific Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 30: Asia-pacific Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 31: Asia-pacific Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 32: Asia-pacific Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 33: Asia-pacific Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million); Table 34: Latin America Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 35: Latin America Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 36: Latin America Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 37: Latin America Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 38: Latin America Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 39: Latin America Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 40: Latin America Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million); Table 41: Middle East And Africa Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 42: Middle East And Africa Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 43: Middle East And Africa Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 44: Middle East And Africa Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 45: Middle East And Africa Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 46: Middle East And Africa Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 47: Middle East And Africa Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million)
Figures List: Figure 1: Technology Snapshot; Figure 2: Market Maturity Analysis; Figure 3: Global Ophthalmic Drugs Market, By Type, 2022 & 2030 (In %); Figure 4: Global Ophthalmic Drugs Market, By Prescription Drugs, 2023-2030 (In $ Million); Figure 5: Global Ophthalmic Drugs Market, By Over-the-counter Drugs, 2023-2030 (In $ Million); Figure 6: Global Ophthalmic Drugs Market, By Condition, 2022 & 2030 (In %); Figure 7: Global Ophthalmic Drugs Market, By Dry Eye, 2023-2030 (In $ Million); Figure 8: Global Ophthalmic Drugs Market, By Glaucoma, 2023-2030 (In $ Million); Figure 9: Global Ophthalmic Drugs Market, By Infection/Inflammation/Allergies, 2023-2030 (In $ Million); Figure 10: Global Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Figure 11: Global Ophthalmic Drugs Market, By Retinal Disorder, 2022 & 2030 (In %); Figure 12: Global Ophthalmic Drugs Market, By Wet Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 13: Global Ophthalmic Drugs Market, By Dry Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 14: Global Ophthalmic Drugs Market, By Diabetic Retinopathy, 2023-2030 (In $ Million); Figure 15: Global Ophthalmic Drugs Market, By Other Retinal Disorders, 2023-2030 (In $ Million); Figure 16: Global Ophthalmic Drugs Market, By Other Conditions, 2023-2030 (In $ Million); Figure 17: Global Ophthalmic Drugs Market, By Therapeutic Type, 2022 & 2030 (In %); Figure 18: Global Ophthalmic Drugs Market, By Anti-glaucoma, 2023-2030 (In $ Million); Figure 19: Global Ophthalmic Drugs Market, By Anti-infection, 2023-2030 (In $ Million); Figure 20: Global Ophthalmic Drugs Market, By Anti-inflammatory, 2023-2030 (In $ Million); Figure 21: Global Ophthalmic Drugs Market, By Anti-allergy, 2023-2030 (In $ Million); Figure 22: Global Ophthalmic Drugs Market, By Other Therapeutic Types, 2023-2030 (In $ Million); Figure 23: Global Ophthalmic Drugs Market, By Delivery Method, 2022 & 2030 (In %); Figure 24: Global Ophthalmic Drugs Market, By Gels, 2023-2030 (In $ Million); Figure 25: Global Ophthalmic Drugs Market, By Eye Solutions & Suspensions, 2023-2030 (In $ Million); Figure 26: Global Ophthalmic Drugs Market, By Capsules & Tablets, 2023-2030 (In $ Million); Figure 27: Global Ophthalmic Drugs Market, By Eye Drops, 2023-2030 (In $ Million); Figure 28: Global Ophthalmic Drugs Market, By Ointments, 2023-2030 (In $ Million); Figure 29: Global Ophthalmic Drugs Market, By Channel, 2022 & 2030 (In %); Figure 30: Global Ophthalmic Drugs Market, By Hospital Pharmacies, 2023-2030 (In $ Million); Figure 31: Global Ophthalmic Drugs Market, By Drug Stores, 2023-2030 (In $ Million); Figure 32: Global Ophthalmic Drugs Market, By Online Pharmacies, 2023-2030 (In $ Million); Figure 33: Global Ophthalmic Drugs Market, By Other Channels, 2023-2030 (In $ Million); Figure 34: Global Ophthalmic Drugs Market, By Regional Outlook, 2022 & 2030 (In %); Figure 35: United States Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 36: Canada Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 37: United Kingdom Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 38: Germany Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 39: France Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 40: Italy Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 41: Spain Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 42: Poland Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 43: Rest Of Europe Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 44: China Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 45: Japan Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 46: India Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 47: South Korea Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 48: Asean Countries Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 49: Australia & New Zealand Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 50: Rest Of Asia-pacific Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 51: Brazil Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 52: Mexico Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 53: Rest Of Latin America Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 54: United Arab Emirates Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 55: Turkey Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 56: Saudi Arabia Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 57: South Africa Ophthalmic Drugs Market 2023-2030 (In $ Million); Figure 58: Rest Of Middle East & Africa Ophthalmic Drugs Market 2023-2030 (In $ Million)